Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

A call for uniformity in implementing the IPAF (interstitial pneumonia with autoimmune features) criteria

Adelle S. Jee, Jane F. Bleasel, Stephen Adelstein, Gregory J. Keir, Tamera J. Corte
European Respiratory Journal 2016 48: 1811-1813; DOI: 10.1183/13993003.01259-2016
Adelle S. Jee
1Dept of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia
2Sydney Medical School, University of Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane F. Bleasel
2Sydney Medical School, University of Sydney, Sydney, Australia
3Dept of Rheumatology, Royal Prince Alfred Hospital, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Adelstein
2Sydney Medical School, University of Sydney, Sydney, Australia
4Dept of Clinical Immunology and Allergy, Royal Prince Alfred Hospital, Sydney, Australia
6Immunopathology Laboratory, South-west Sydney Pathology Service, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stephen Adelstein
Gregory J. Keir
5Dept of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamera J. Corte
1Dept of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia
2Sydney Medical School, University of Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tamera.corte@sswahs.nsw.gov.au
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

There is an urgent need to standardise our approach to connective tissue disease classification in ILD and IPAF http://ow.ly/IPm0304nLVV

To the Editor:

We commend Oldham et al. [1] for their recent article using the new European Respiratory Society/American Thoracic Society criteria for interstitial pneumonia with autoimmune features (IPAF) to re-characterise a cohort of interstitial lung disease (ILD) patients in their centre. IPAF defines individuals with interstitial pneumonia and features suggestive of a connective tissue disease (CTD), but not meeting established CTD classification criteria [2]. Of their 422 patients with previously diagnosed idiopathic interstitial pneumonia (IIP) or undifferentiated-CTD ILD (UCTD-ILD), approximately one-third met the IPAF criteria, including nearly 20% of those with idiopathic pulmonary fibrosis, 25% with unclassifiable IIP and almost all of those with UCTD-ILD [1]. Importantly, survival was markedly worse in the IPAF group compared with a CTD-ILD cohort [1]. Within the IPAF domains, the presence of at least one clinical criterion was predictive of a favourable outcome, while morphological, multi-compartment involvement carried a significantly increased risk of mortality [1].

Interestingly, only one patient in their IPAF cohort had detectable anti-tRNA synthetase antibodies [1], presumably because patients with myositis-specific antibodies were considered to have CTD-ILD, even in the absence of systemic features of idiopathic inflammatory myopathy (IIM). Physicians often face the challenge of interpreting the significance of a positive autoantibody result in an ILD patient with no systemic manifestations of a CTD, especially when definitive rheumatological criteria have not been established. Such is the case with the IIMs, a group of systemic autoimmune conditions including polymyositis and dermatomyositis (DM). Our awareness of IIMs is critical as ILD occurs in over 50% of those affected and is the chief determinant of disease progression and prognosis [3].

Since 1970, there have been numerous suggested criteria for the diagnosis and classification of the IIMs [4]. Updated criteria incorporate IIM subgroups based on autoantibody profiles, but there remains no international agreement on how or if such immunoassays should be included [4, 5]. This variation between definitions can lead to major differences in how a patient with positive myositis antibodies is classified: either as IPAF or CTD-ILD; as demonstrated by Oldham et al.'s [1] cohort where such patients were considered to have “anti-synthetase syndrome” and thus CTD-ILD. We believe standardisation of the IIM classification used across our ILD populations is essential, as the inclusion or exclusion of these patients in IPAF cohorts in future studies may have major ramifications for our understanding and further research of IPAF.

Myositis autoantibodies are present in up to 40% of patients with IIMs and are associated with an increased risk of ILD (table 1) [7, 8]. Anti-tRNA synthetase antibodies are the most commonly detected, and are present in 25–35% of all IIM patients and up to two-thirds of those who demonstrate ILD [5, 7, 8]. Anti-Jo1 is the most common of the eight identified anti-synthetase antibodies [7]. The presence of anti-tRNA synthetase antibodies is thought to characterise a unique phenotype, known as “anti-synthetase syndrome”, which carries a substantial risk of ILD and increased mortality. Diagnosis remains very challenging due to significant variability in the degree and timing of other features that may include myositis, arthritis, Raynaud's phenomenon, mechanic's hands, skin rashes, sicca syndrome and fever, and ILD can predominate with subclinical myositis in a significant proportion [5, 6]. Fundamental questions remain unanswered. How do we interpret the presence of auto-antibodies in the absence of other definitive features? What are the implications for management? There is an urgent need to standardise and validate revised definitions of anti-synthetase syndrome, such as that proposed by Connors et al. [7].

View this table:
  • View inline
  • View popup
TABLE 1

Myositis autoantibodies associated with interstitial lung disease (ILD)

These problems are not just limited to anti-synthetase antibodies. The anti-CADM-140 antibody (also known as anti-MDA5) is associated with “clinically amyopathic DM” and rapidly progressive ILD (CADM-ILD), which has a 6-month survival rate of only 40–55% [9]. Anti-CADM antibodies have a potential vital role in early identification of CADM-ILD requiring aggressive immunosuppression, but without a clear definition for CADM, research on a uniform cohort remains difficult.

Just as previous research on the patient group now identifiable as IPAF was hindered by inconsistent nomenclature, there is a parallel and urgent need to standardise our approach to the evaluation of CTD in our ILD clinics. An added complication is the lack of standardisation of testing and interpretation of autoantibody results. We await with interest the results of the “International Myositis Classification Criteria Project”, a multidisciplinary project launched by the International Myositis Assessment and Clinical Studies Group, sponsored by the National Institute of Environmental Health Sciences of Health and supported by the American College of Rheumatology, European League Against Rheumatism, and The Myositis Association. With enrolment complete and analysis in progress, the goal of the study is to develop consensus classification criteria for the IIMs [10].

We strongly believe there is a need for the ILD community to agree which myositis criteria to use when evaluating our patients. Authors of the IPAF statement recognise that the listed antibodies and serological criteria may require modification as our knowledge evolves [2]. We do not know what the optimum “list” is, but the IPAF classification is a first important step towards developing a minimum dataset that will help determine which criteria should be recommended for clinical practice. If we do not work promptly with rheumatologists, immunologists and internists to standardise our approach to serological testing and rheumatological disease classification, ILD patients with ill-defined extrapulmonary features may continue to fall under different diagnostic umbrellas (i.e. IPAF versus CTD-ILD), which will continue to threaten our ability to make accurate comparisons and conclusions about the natural history and clinical implications of IPAF.

Footnotes

  • Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

  • Received June 24, 2016.
  • Accepted August 17, 2016.
  • Copyright ©ERS 2016

References

  1. ↵
    1. Oldham JM,
    2. Adegunsoye A,
    3. Valenzi E, et al.
    Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J 2016; 47: 1767–1775.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Fischer A,
    2. Antoniou KM,
    3. Brown KK, et al.
    An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46: 976–987.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Fathi M,
    2. Vikgren J,
    3. Boijsen M, et al.
    Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59: 677–685.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Sultan SM,
    2. Isenberg DA
    . Re-classifying myositis. Rheumatology (Oxford) 2010; 49: 831–833.
    OpenUrlFREE Full Text
  5. ↵
    1. Mahler M,
    2. Miller FW,
    3. Fritzler MJ
    . Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 2014; 13: 367–371.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Ghirardello A,
    2. Borella E,
    3. Beggio M, et al.
    Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights 2014; 5: 69–75.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Connors GR,
    2. Christopher-Stine L,
    3. Oddis CV, et al.
    Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 2010; 138: 1464–1474.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Lega JC,
    2. Reynaud Q,
    3. Belot A, et al.
    Idiopathic inflammatory myopathies and the lung. Eur Respir Rev 2015; 24: 216–238.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Ikeda S,
    2. Arita M,
    3. Morita M, et al.
    Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split? BMC Pulm Med 2015; 15: 159.
    OpenUrlCrossRefPubMed
  10. ↵
    NIEHS. Classification Criteria Study: The International Myositis Classification Criteria Project. www.niehs.nih.gov/research/resources/imacs/classificationcriteria/index.cfm Date last accessed: August 7, 2016. Date last updated: March 31, 2015.
PreviousNext
Back to top
View this article with LENS
Vol 48 Issue 6 Table of Contents
European Respiratory Journal: 48 (6)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A call for uniformity in implementing the IPAF (interstitial pneumonia with autoimmune features) criteria
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
A call for uniformity in implementing the IPAF (interstitial pneumonia with autoimmune features) criteria
Adelle S. Jee, Jane F. Bleasel, Stephen Adelstein, Gregory J. Keir, Tamera J. Corte
European Respiratory Journal Dec 2016, 48 (6) 1811-1813; DOI: 10.1183/13993003.01259-2016

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
A call for uniformity in implementing the IPAF (interstitial pneumonia with autoimmune features) criteria
Adelle S. Jee, Jane F. Bleasel, Stephen Adelstein, Gregory J. Keir, Tamera J. Corte
European Respiratory Journal Dec 2016, 48 (6) 1811-1813; DOI: 10.1183/13993003.01259-2016
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Association between immunosuppressants and outcomes of COVID-19
Show more Agora

Correspondence

  • Clinical outcomes of bronchiectasis in India
  • Reply: Clinical outcomes of bronchiectasis in India
  • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society